SIGN UP

Sign up to get updates about our clinical trials and other exciting news close

LIGHTING THE WAY
TO A NEW TREATMENT
POSSIBILITY

LIGHTING THE WAY
TO A NEW TREATMENT
POSSIBILITY

At a Glance

The goal of the Illuminate 301 clinical trial is to evaluate the comparison of FDA approved Yervoy® (ipilimumab) alone and Yervoy® (ipilimumab) together with tilsotolimod (IMO-2125) in patients with metastatic melanoma who have shown signs of disease progression while on Opdivo® (nivolumab) or Keytruda® (pembrolizumab).

  • PATIENT ENROLLMENT

    adults who have metastatic melanoma that has
    progressed on or after available anti-PD-1 treatments

  • ENROLLMENT GOAL

    Approximately300
    patients

  • STUDY DRUG

    Tilsotolimod (IMO-2125) plus Yervoy® (ipilimumab) or Yervoy® alone

*Additional eligibility criteria apply. Please contact your doctor for more detailed information about the study.
Yervoy® and Opdivo® are registered trademarks of Bristol-Myers Squibb. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Study overview

If you are enrolled in the study, you will be assigned by chance to 1 of 2 treatment groups—group A or group B. If enrolled, you have an equal chance of being assigned to either group.

Group A patients will receive Yervoy up to 4 times.

Group B patients will receive tilsotolimod up to 9 times, 4 of which will be in combination with Yervoy.

*Yervoy® is a registered trademark of Bristol-Myers Squibb Company.

Eligibility requirements

You may be eligible to participate in the study if you*

  • are age 18 years or older
  • have a diagnosis of metastatic melanoma (melanoma that has spread to other parts of your body)
  • have melanoma that has progressed on or after treatment with anti-PD-1s (such as, Opdivo® [nivolumab] or Keytruda® [pembrolizumab])
  • You might not be eligible to participate if you have melanoma in or around the eye, a condition known as ocular melanoma

Before you can be enrolled in a study, you must undergo a process called screening, during which the study team will evaluate whether you qualify to participate.

*Additional eligibility criteria apply. Please speak to your doctor for more detailed information about the study.
Yervoy® and Opdivo® are registered trademarks of Bristol-Myers Squibb Company. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact information

If you would like to learn more about this study or speak with someone on our team, please contact us.

1-877-888-6550 ext. 2 (U.S. toll free) or 484-348-1600